Today’s targeted infectious disease diagnostics limit testing to the most common pathogens associated with a clinical syndrome. This leaves infections undiagnosed and may lead to additional downstream testing, patient dissatisfaction, and compromised patient care.
The BioFire® FilmArray® System uses syndromic testing to identify infectious diseases with several FDA-cleared and CE-marked assay-specific reagent panels. Each panel combines a broad grouping of probable pathogenic causes into a single, rapid test, requires only two minutes of hands-on time, and has about an hour turnaround time. This allows physicians to easily choose the right test, the first time.
Products and Services
BioFire’s molecular solutions feature unmatched usability and speed, setting a new standard in molecular diagnostic platforms. The BioFire® FilmArray® System and comprehensive panels empower all members of the care team to make better diagnostic decisions using the syndromic approach.
The Latest News at BioFire
BioFire is committed to constant innovation and continual improvement. Stay up-to-date on the most recent announcements about developments and defining moments at BioFire in the links below.
Please click to learn more about:
The BioFire® Respiratory 2.1-EZ (RP2.1- EZ) Panel* With SARS-CoV-2
BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization
bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test
Click Here For More Press Releases